US regulators fast-track novel leukemia therapy

The FDA is looking to speed up the availability of a new technique that put 89 percent of cancer patients into remission. Here’s the story.

“The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated a “breakthrough therapy” by the US Food and Drug Administration.

That means the experimental therapy will benefit from a speedier than average review process and will get extra attention from the FDA toward development for market.”